Hansoh Pharmaceutical Group
$34.14Change from previous close: −3.29%Absolute change: −$1.16
At a glance
- Revenue growth
- +22.57%
- 2025 vs 2024
- Net income growth
- +27.07%
- 2025 vs 2024
- Net margin
- 37.0%
- 2024: 35.7%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 15,028 | 12,261 | 10,104 | 9,382 | 9,935 |
| Cost of revenue | 1,519 | 1,117 | 1,033 | 870 | 870 |
| Gross profit | 13,509 | 11,144 | 9,071 | 8,512 | 9,065 |
| Selling, general and administrative | 4,736 | 4,508 | 4,241 | 4,148 | 4,371 |
| Research and development | 3,358 | 2,702 | 2,097 | 1,693 | 1,797 |
| Operating income | 5,401 | 3,902 | 2,679 | 2,607 | 2,821 |
| EBIT | 5,401 | 3,902 | 2,679 | 2,607 | 2,821 |
| EBITDA | 5,764 | 4,278 | 3,025 | 2,932 | 3,084 |
| Interest expense | 3.2 | 6.7 | 66.7 | 58.1 | 52.8 |
| Pre-tax income | 6,551 | 5,085 | 3,766 | 2,948 | 3,300 |
| Income tax | 995 | 713 | 489 | 365 | 587 |
| Net income | 5,555 | 4,372 | 3,278 | 2,584 | 2,713 |
| Net income to common shareholders | 5,555 | 4,372 | 3,278 | 2,584 | 2,713 |
| Basic EPS | 0.93 | 0.74 | 0.55 | 0.44 | 0.46 |
| Diluted EPS | 0.93 | 0.73 | 0.52 | 0.44 | 0.44 |
| Average shares (basic) | 5,963 | 5,930 | 5,925 | 5,916 | 5,921 |
| Average shares (diluted) | 5,981 | 5,950 | 6,020 | 5,929 | 5,998 |
| Dividend per share | 0.39 | 0.32 | 0.19 | 0.09 | 0.07 |